Skip to main content

Table 1 Baseline clinical characteristics and quality of life in PLWHIV diagnosed with HAND who participated in a randomised clinical controlled trial to test the effects of aerobic activity on QoL

From: Effects of aerobic exercise on quality of life of people with HIV-associated neurocognitive disorder on antiretroviral therapy: a randomised controlled trial

Approach Intention-to-treat Per protocol
Variables Group Statistics Group  
Exp (n = 38) Control (n = 35) Exp (n = 32) Control (n = 35)
MR MR MWU-value p x̅(SD)/MR x̅ ± (SD)/MR t/MU-value p
Depression (BDI) 141.23 138.69 367.00 0.946 36.20 36.81 636.500 0.900
ART adherence 178.90 165.14 520.88 0.001* 34.98 32.02 495.50 0.171
SPO2 172.64 194.24 563.75 0.044* 34.45 38.67 571.500 0.377
Heart rate 164.74 202.83 505.96 0.001* 73.70 (10.65) 77.57 (9.68) − 1.610 0.112
Systolic BP 177.14 184.25 596.63 0.515 36.20 36.81 636.500 0.901
Diastolic BP 215.47 145.65 389.15 < 0.001* 38.97 27.32 351.000 0.013*
Physical QoL 163.77 194.84 505.89 0.004* 44.97 (14.94) 49.37 (16.18) − 1.191 0.238
Psychological QoL 175.91 190.70 587.60 0.686 53.75 (17.37) 56.11 (14.52) − 0.621 0.536
Social relationship QoL 161.97 191.20 496.73 0.006* 32.71 38.29 515.000 0.247
Environmental QoL 174.99 188.46 582.50 0.217 49.63 (15.71) 50.69 (13.60) − 0.301 0.764
Overall QOL 165.11 201.29 509.62 0.001* 45.76 (12.32) 49.66 (7.65) − 1.603 0.113
  1. Data for the exercise (Exp) and control groups are shown
  2. MR: Mean rank; MWU: Mann–Whitney test; x̅ (SD): mean (standard deviation); t: t-value
  3. *: significant at alpha = 0.05